Management of Nephrotic Syndrome with CKD
Manage nephrotic syndrome with CKD using a comprehensive, stepwise approach prioritizing edema control with loop diuretics, blood pressure management with ACE inhibitors or ARBs, sodium restriction, and close monitoring for complications including thromboembolism and cardiovascular disease. 1
Edema Management
Loop diuretics are first-line therapy for edema control. 1
- Dosing strategy: Use twice-daily dosing (preferred over once daily); daily dosing may be acceptable when GFR is reduced 1
- Dose escalation: Increase dose until clinically significant diuresis occurs or maximum effective dose is reached
- Alternative loop diuretics: Switch to bumetanide or torsemide if furosemide fails or if oral bioavailability is a concern 1
Diuretic-Resistant Edema
For resistant edema, combine loop diuretics with mechanistically different diuretics for synergistic effect 1:
- Thiazide-like diuretics (any high-dose thiazide equally effective) with oral or IV loop diuretic to block distal sodium reabsorption
- Amiloride: Improves edema/hypertension, counters hypokalemia, helps with metabolic alkalosis
- Spironolactone: Improves edema/hypertension, counters hypokalemia (monitor for hyperkalemia, especially with RAS blockade)
- Acetazolamide: May help treat metabolic alkalosis (weak diuretic)
For truly refractory cases: Consider loop diuretics with IV albumin, ultrafiltration, or hemodialysis 1
Critical Monitoring for Diuretic Adverse Effects 1
- Hypokalemia (thiazide and loop diuretics)
- Hyponatremia (thiazide diuretics)
- Impaired GFR
- Hyperkalemia (spironolactone/eplerenone, especially with RAS blockade)
- Volume depletion (particularly in pediatric/elderly patients)
Sodium Restriction
Restrict dietary sodium to <2.0 g/day (<90 mmol/day). 1 This is fundamental to edema management and works synergistically with diuretics.
Blood Pressure and Proteinuria Management
Use ACE inhibitor or ARB uptitrated to maximally tolerated dose as first-line therapy for hypertension and proteinuria. 1
Key Implementation Points
- Target systolic BP: <120 mm Hg using standardized office measurement (practically achievable at 120-130 mm Hg in most patients with glomerular disease) 1
- Do NOT stop ACEi/ARB with modest and stable serum creatinine increase (up to 30%) 1
- STOP ACEi/ARB if kidney function continues to worsen or refractory hyperkalemia develops 1
Critical Caveat
Do NOT start ACEi/ARB in patients presenting with abrupt onset nephrotic syndrome - these drugs can cause AKI, especially in minimal change disease 1. Wait until disease is characterized and stabilized.
Cardiovascular Risk Management
Nephrotic syndrome with CKD carries substantially elevated cardiovascular risk - up to two-fold increase in myocardial infarction and stroke 2.
Lipid Management
Treat dyslipidemia aggressively with statins as primary therapy. 3, 2, 4 The dyslipidemia in nephrotic syndrome includes:
- Elevated cholesterol, triglycerides, VLDL, and IDL
- Decreased lipoprotein lipase activity
- Increased PCSK9 levels 4
Additional lipid-lowering options include bile acid sequestrants, fibrates, ezetimibe, and potentially PCSK9 inhibitors 4. Standard cardiovascular risk scores underestimate true risk in nephrotic syndrome as they lack nephrotic-specific parameters 2.
Thromboembolism Prevention
Nephrotic syndrome carries an eight-fold increased risk of venous thromboembolism, particularly with membranous nephropathy. 2
Anticoagulation Strategy
Consider anticoagulation for patients with serum albumin <2.5 g/dL and elevated VTE risk. 2 This is driven by:
- Urinary loss of natural anticoagulants
- Increased procoagulant factors
- Platelet activation 2
Low-dose aspirin may be indicated where arterial thrombosis prophylaxis is needed 2.
Lifestyle Modifications
Beyond pharmacotherapy, encourage 5:
- Physical activity: Moderate-intensity for cumulative 150 minutes per week (compatible with cardiovascular tolerance and frailty level)
- Avoid sedentary behavior
- Weight optimization for those with obesity
- Smoking cessation
Monitoring Strategy
Quantify proteinuria regularly as it has disease-specific relevance for prognosis and treatment decisions 1. Proteinuria goal is typically <1 g/day, though variable depending on primary disease process 1.
Monitor urine sediment for erythrocyte morphology, red cell casts, and acanthocytes 1.
Additional Complications to Monitor
- Infections: Increased susceptibility due to urinary immunoglobulin loss 3, 6
- Acute kidney injury: Can occur from volume depletion, infection, or medication effects 3
- Malnutrition: From urinary protein loss 6
- Progressive CKD: Requires nephrology co-management and consideration of kidney failure risk prediction 5
Disease-Specific Treatment
The underlying cause of nephrotic syndrome (minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, secondary causes) will dictate immunosuppressive therapy needs 3. Kidney biopsy is usually required to define the entity and guide specific treatment 3, 6.